Navigation Links
Mach One Corporation Developing a Nasal, Hand Carried Product as Solution to Swine Flu (H1N1) Virus
Date:6/4/2009

Product Will Create A Barrier To Block The Attachment Of The Virus To The Nasal Membranes

BELGIUM, Wis., June 4 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), an innovative, global wellness solutions company, announces the development of a nasal immunoglobulins based product that can be hand carried and used as needed to form a mechanical barrier to block the attachment of the virus to the nasal membranes.

Peter Nash, Ph.D. and Chief Science Officer of Mach One Corporation said, "Having worked with the influenza virus group since 1974, the current strain of influenza Swine Flu (H1N1) appears to be similar to the swine influenza A (H1N1) triple reassortant virus, A/Wisconsin/87/2005 H1N1. This strain of virus is in the influenza virus group that is one of the most frequently occurring human illnesses and is responsible for substantial morbidity and economic loss. Viral inhibitors in the form of active immunoglobulins are effective anti-viral agents in vitro and in vivo. The primary site of attachment for these viruses appears to be in the nasal membrane. They spread from the nasal region into the pharyngeal region and can lead to lower respiratory infection leading to pneumonia and possible death. The proposed new product line could be engineered to be carried in one's pocket and used in the nasal passage. There is no need to be exposed to the risk of a needle. As needed, this type of product would allow for delivery to the direct area of the nasal membrane and block initial attachment in the nasal membrane. This gives a mechanical barrier to protect the person until their own immune system can build-up protection. This should slow the frequency of the virus in the environment."

Dr. Nash continued, "When blockage of the attachment of the virus is the objective, the immunoglobulin package is supplied to humans prior to exposure or immediately after an outbreak. The substantial prevention of viruses in the nasal pharyngeal region tract of humans will ultimately permit substantial reduction or elimination of the virus. This repression or blocking of virus will permit a significant decrease in shedding and passage of the virus from host to host. In addition, the resulting decrease in shedding should further enhance the prevention of epidemic and pandemics."

About Mach One Corporation:

Mach One Corporation (www.machonecorp.com) is a global wellness company that provides biotechnology based solutions to help address one of the world's most pressing and costly needs--positive, long-term health and longevity benefits for humans and disease-threatened animals of commercial operations. While animal wellness, organic and sustainable products are our initial primary focus, we intend in the near future to add Nutraceuticals to our growing list of operating groups. As an ongoing objective we intend to be agile and swift in spotting business opportunities and respective businesses to expand our vision for positive contribution to global wellness.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):